Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ICML 2021

Latest Updates

View all
7:00
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma
Andrés Ferreri • 9 Jun 2021
2:39
Advances in lymphoma imaging
Sally Barrington • 9 Jun 2021
1:55
PET scans in NHL
Sally Barrington • 9 Jun 2021
4:50
PET-adapted treatment in PMBCL
Eliza Hawkes • 9 Jun 2021

Non-Hodgkin Lymphoma

View all
3:44
ELARA: tisa-cel in R/R follicular lymphoma
Nathan Fowler • 18 Jun 2021
7:00
IELSG32 trial: 88-month follow-up on MATRIX followed by auto-SCT in primary CNS lymphoma
Andrés Ferreri • 9 Jun 2021
1:44
Genetics and biomarkers in diagnosing and treating lymphoma
Ash Alizadeh • 17 Jun 2021
4:50
PET-adapted treatment in PMBCL
Eliza Hawkes • 9 Jun 2021

CLL

View all
3:56
TRANSCEND-CLL-004: liso-cel in CLL
William Wierda • 18 Jun 2021
1:18
Pirtobrutinib: The next generation of BTK inhibitors
Barbara Eichhorst • 8 Jun 2021

Immuno-Oncology

View all
5:35
MCL0208: identification of novel genomic prognostic factors
Simone Ferrero • 16 Jun 2021
1:56
The future of CAR T-cell therapies in hematologic malignancies
Nathan Fowler • 18 Jun 2021
Visit the Lymphoma Channel for the latest updates from leading experts

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals